Cyclo Therapeutics, Inc. (CYTHW)

Market Cap	21.86M
Revenue (ttm)	870,725
Net Income (ttm)	-24.80M
Shares Out	28.77M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,450
Open	0.221
Previous Close	0.220
Day's Range	0.185 - 0.228
52-Week Range	0.050 - 0.614
Beta	-0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 19, 2025

About CYTHW

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, prim...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTHW
• Website: https://cyclotherapeutics.com

Financial Performance

In 2023, Cyclo Therapeutics's revenue was $1.08 million, a decrease of -21.76% compared to the previous year's $1.38 million. Losses were -$20.06 million, 29.8% more than in 2022.